Welcome to our dedicated page for Enzon Pharma SEC filings (Ticker: ENZN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enzon Pharmaceuticals, Inc. (ENZN) files a range of documents with the U.S. Securities and Exchange Commission that are central to understanding its role as a public company acquisition vehicle and its proposed merger with Viskase Companies, Inc. On this page, you can review Enzon’s Form 8-K current reports, which detail material events such as the execution of the Agreement and Plan of Merger, subsequent amendments to that agreement, and changes to its Section 382 Rights Agreement.
Merger-related 8-K filings describe the structure of the all-stock transaction in which Viskase will merge with and into a wholly owned Enzon subsidiary, the exchange ratios between Viskase common stock, Enzon common stock, and Enzon’s Series C Non-Convertible Redeemable Preferred Stock, and the anticipated post-merger ownership split, including the expectation that current Viskase stockholders will own 55% of the combined company following the amended merger terms. These filings also outline requirements such as a 1-for-100 reverse stock split of Enzon common stock and the role of Icahn Enterprises Holdings L.P. and its affiliates under a support agreement.
Other key filings relate to Enzon’s Section 382 Rights Agreement. Through multiple amendments reported on Form 8-K, Enzon has adjusted the Final Expiration Date of the rights issued under this agreement. The company notes that these amendments are intended to revise the expiration date while leaving the rest of the agreement unchanged, and that management believes the revised dates are in the best interests of stockholders.
Enzon has also stated that it intends to file a registration statement on Form S-4 in connection with the Viskase merger. That filing is expected to contain a consent solicitation statement and prospectus and to include financial information about the combined company. On this page, AI-powered tools can help summarize lengthy filings, highlight key transaction terms, and make it easier to understand complex documents such as merger agreements, rights agreements, and related exhibits.
Enzon Pharmaceuticals, Inc. entered into an Eighth Amendment to its Section 382 Rights Agreement, moving the Final Expiration Date for the rights from March 2, 2026 to noon, New York City time, on March 11, 2026. No other terms of the rights plan were changed.
Enzon also extended the expiration date of its exchange offer to swap Series C Non-Convertible Redeemable Preferred Stock for Enzon common stock. The offer now expires one minute after 11:59 p.m., Eastern time, on March 9, 2026, unless extended. The filing also references an S-4 registration statement for the proposed merger with Viskase Companies, Inc.
Enzon Pharmaceuticals amended its Schedule TO to report results and extend its exchange offer for Series C Non-Convertible Redeemable Preferred Stock into common stock.
The company extended the offer expiration to one minute after 11:59 p.m., Eastern Time, on March 9, 2026. The depositary reported that 12 shares had been validly tendered and not withdrawn as of 5:00 p.m., Eastern Time, on February 26, 2026, representing less than 0.001% of the 40,000 shares outstanding as of that date.
Enzon Pharmaceuticals is providing an information statement describing a planned change in board control tied to a pending merger with Viskase. Under the Merger Agreement, Merger Sub will merge into Viskase and the combined company will operate as Viskase Holdings, Inc. with common stock quoted on the OTCQB. The Closing is anticipated prior to March 31, 2026. Upon Closing the Board will expand to seven members and the disclosed nominees include Robert Flint, Colin Kwak, Dustin DeMaria, Kenneth Shea and Peter K. Shea; Thomas D. Davis will be CEO of the Combined Company. A consent solicitation approved a 1-for-100 reverse stock split and adoption of the Merger Proposal; as of the record date there were 74,214,603 shares outstanding and the Merger Proposal received consents representing 42,350,448 shares (57.1%). The information statement discloses related‑party transactions and that the IEH Parties (affiliated with Carl C. Icahn) are expected to beneficially own approximately 93.32% of the Combined Company following the Merger.
Enzon Pharmaceuticals filed an amendment to its tender offer statement covering an exchange offer in which each share of Series C Non-Convertible Redeemable Preferred Stock may be exchanged for common stock equal to the share’s aggregate liquidation preference divided by $7.83 after a reverse stock split.
The amendment reports that, as of 8:00 a.m. Eastern on February 11, 2026, a sufficient number of stockholders consented to approve Enzon’s proposals. The reverse stock split proposal was approved by holders of 40,993,338 common shares, or 55.2% of shares outstanding, and the merger proposal was approved by holders of 42,350,448 common shares, or 57.1%. These approvals represent a majority of the 74,214,603 Enzon common shares outstanding as of the January 29, 2026 record date, though closing of the merger transactions remains subject to remaining conditions in the merger agreement.
Enzon Pharmaceuticals reported that stockholders have delivered enough written consents to approve two key proposals tied to its planned merger with Viskase. The Reverse Stock Split Proposal received approval from holders of 40,993,338 shares of Enzon common stock, representing 55.2% of issued and outstanding shares. The Merger Proposal was approved by holders of 42,350,448 shares, or 57.1% of the issued and outstanding shares. As of the January 29, 2026 record date, 74,214,603 shares were outstanding and entitled to vote. The consent period ended on February 11, 2026, and closing of the merger remains subject to satisfaction or waiver of remaining conditions in the Merger Agreement.
Enzon Pharmaceuticals, Inc. reported that its stockholders have approved key proposals related to its planned merger with Viskase and a reverse stock split through a consent solicitation.
The Reverse Stock Split Proposal was approved by holders of 40,993,338 shares of Enzon common stock, representing 55.2% of issued and outstanding shares. The Merger Proposal was approved by holders of 42,350,448 shares, or 57.1% of issued and outstanding shares, based on 74,214,603 shares outstanding as of the January 29, 2026 record date.
A sufficient number of consents were received by 8:00 a.m. Eastern Time on February 11, 2026, at which point the consent period and revocation rights ended. Closing of the merger transactions remains subject to satisfaction or waiver of the remaining conditions in the Merger Agreement, as described in the Enzon–Viskase registration statement on Form S-4.
Carl Icahn and his affiliated entities report a 48.6% stake in Enzon Pharmaceuticals, Inc., holding 36,056,636 shares of common stock with shared voting and dispositive power. The filing is Amendment No. 18 to their Schedule 13D on Enzon.
Icahn, Icahn Enterprises Holdings L.P., and Icahn Enterprises G.P. Inc. each report the same 36,056,636 shares as beneficially owned, with no sole voting or dispositive power. The filing notes they may also be deemed to beneficially own shares of preferred stock, though those are not quantified here.
Under a previously disclosed IEH Support Agreement among Icahn Enterprises Holdings affiliates, Enzon and Viskase, Icahn-affiliated holders delivered a written consent on January 30, 2026 approving a proposed merger and an amendment to Enzon’s certificate of incorporation, using all Enzon shares they hold.
Enzon Pharmaceuticals has launched an issuer tender offer to exchange each share of its Series C Non-Convertible Redeemable Preferred Stock for common stock. The number of common shares per preferred share equals that share’s aggregate liquidation preference divided by $7.83, after a reverse stock split.
The offer is aimed at all holders of the 40,000 outstanding Series C preferred shares and is linked to Enzon’s planned merger with Viskase Companies, Inc.. Completion of the exchange offer depends on all merger conditions being satisfied, including effectiveness of Enzon’s Form S-4 registration statement and required stockholder written consent approving the merger.
As of January 30, 2026, Enzon had 74,214,603 common shares and 40,000 Series C preferred shares outstanding. Cash in lieu of fractional common shares will come from Enzon’s cash on hand, and the company explicitly makes no recommendation on whether preferred holders should tender.
Enzon Pharmaceuticals is soliciting written consents and offering to issue up to 7,935,878 shares of common stock in connection with its planned merger with Viskase Companies and a related exchange of Enzon Series C preferred stock for common stock.
Merger Sub will merge into Viskase, which will become a wholly owned Enzon subsidiary and then convert into a Delaware LLC, with the combined public company renamed Viskase Holdings, Inc. and quoted on the OTCQB. Before closing, Enzon seeks stockholder approval for a 1‑for‑100 reverse stock split of its common stock and adoption of the merger agreement via written consents rather than a meeting.
Assuming full participation in the preferred exchange and an agreed share exchange with Icahn Enterprises affiliates, current Enzon common holders are expected to own about 5% of the combined company, Enzon Series C preferred holders about 40%, and Viskase common holders about 55%. Icahn-related entities already control a majority of both Enzon and Viskase voting power and have agreed, with certain exceptions, to support the Enzon proposals.